2024-03-28T16:49:35Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/718632022-11-17T02:08:08Zhdl_2115_20043hdl_2115_137The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose MonitoringYanagiya, ShingoCho, Kyu YongNakamura, AkinobuNomoto, HiroshiKawamoto, YasuyukiKawakubo, KazumichiKomatsu, YoshitoMitsuhashi, TomokoMiyoshi, HideakiAtsumi, Tatsuyaeverolimushypoglycemiacontinuous glucose monitoring490An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM.The Japanese Society of Internal MedicineJournal Articleapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/2115/71863https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/71863/11/57_0126-17.pdfhttps://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/71863/4/57_0126-17_1.pdfhttps://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/71863/3/57_0126-17_2.pdfhttps://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/71863/2/57_0126-17_3.pdfhttps://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/71863/1/57_0126-17_4.pdf0918-2918Internal medicine5717252725312018-09-01enginfo:doi/10.2169/internalmedicine.0126-17https://creativecommons.org/licenses/by-nc-nd/4.0/publisher